Unit: Drug Discovery and Development
Harrison School of Pharmacy
3306a Walker Building
Auburn, AL 36849
Alzheimer's disease is the leading cause of cognitive impairment in the geriatric population where short-term and recent memory deficits occur with the progressive degeneration of cognitive functioning. Eventually, memory loss becomes so severe that patients lose the ability to care for themselves. Prevalence of Alzheimer's disease is expected to triple over the next half-century. Treatments that slow or halt the progression of Alzheimer's disease would significantly impact quality of life for both the patient and their caretakers and relieve a financial burden on the family and society at large.
My current research is to facilitate and improve the care of patients with Alzheimer’s disease by developing a cost-effective anti-Alzheimer’s drug that has the added benefit of enhancing the memory and neuroprotective effect by applying contemporary scientific methods of investigation.
M. Dhanasekaran, Holcomb LA, Hitt AR, Tharakan B, Porter J, Young KA, Manyam B. Centella asiatica extract selectively decreases amyloid β levels in hippocampus of Alzheimer’s disease animal model. Phytother Res (Accepted).
K. Parameshwaran, M. Dhanasekaran and V. Suppiramaniam, Amyloid beta peptides and glutamatergic synaptic dysregulation, Exp Neurol 210 (2008) 7-13.
S. Uthayathas, S.S. Karuppagounder, S.I. Tamer, K. Parameshwaran, T. Degim, V. Suppiramaniam and M. Dhanasekaran, Evaluation of neuroprotective and anti-fatigue effects of sildenafil, Life Sci 81 (2007) 988-992.